Skip to content
Screener

Niagen Bioscience NAGE Q4 2025 Annual earnings

Reported March 4, 2026 · After market close

Revenue$33.8MBeat by $2.1M
EPS$0.03Beat by $0.01
Revenue estimate$31.7M
EPS estimate$0.02

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$34.4M
EPS estimate$0.01

Financials

Q4 2025

Income statement

See full
Revenue$33.8M+16.2%
Gross profit$21.7M+19.3%
Operating income$4.1M-42.5%
Net income$4.1M-42.4%
EPS (diluted)$0.05-44.4%

Balance sheet

See full
Cash & equivalents$64.8M+45.1%
Total debt$2.8M+7.2%
Total equity$76.5M+66.0%
Total assets$106.4M+55.8%

Cash flow

See full
Operating cash flow$679.0K-92.1%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$507.57M—
Enterprise value$445.58M—
P/E29.2×—
P/S3.9×—

Profitability

See full
Gross margin64.3%+2.4pp
Operating margin12.6%+4.8pp
Net margin13.4%+4.8pp

Returns & leverage

See full
Return on equity28.3%+5.4pp
Debt / equity0×0.0×
Current ratio4.9×+1.3×

FAQ

When did Niagen Bioscience report Q4 2025 earnings?
Niagen Bioscience (NAGE) reported Q4 2025 earnings on March 4, 2026 after market close.
What were Niagen Bioscience's Q4 2025 revenue and EPS?
Niagen Bioscience reported revenue of $33.8M and eps of $0.03 for Q4 2025.
Did Niagen Bioscience beat estimates in Q4 2025?
Revenue beat the consensus estimate of $31.7M by $2.1M. EPS beat the consensus estimate of $0.02 by $0.01.
How did Niagen Bioscience's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 16.2% from $29.1M a year earlier and eps grew 0.0% from $0.03.
Where can I find Niagen Bioscience's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001386570-26-000014) and the 10-K periodic report (0001386570-26-000013) directly on SEC EDGAR. The filing index links above go to sec.gov.